Tumor angiogenesis and novel antiangiogenic strategies

被引:111
作者
Gordon, Michael S. [1 ]
Mendelson, David S. [1 ]
Kato, Gerry [1 ]
机构
[1] Premiere Oncol Arizona, Scottsdale, AZ 85258 USA
关键词
angiogenesis; VEGFR; PDGFR; breast cancer; targeted agents; ENDOTHELIAL GROWTH-FACTOR; METASTATIC BREAST-CANCER; FACTOR EXPRESSION; CARCINOMA CELLS; IN-VIVO; C-KIT; MECHANISMS; INHIBITOR; THERAPY; PLUS;
D O I
10.1002/ijc.25026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is essential for the development and growth of tumors. It is a highly regulated process that requires cross-talk between signaling pathways at all stages of blood vessel development and tumor growth, from the recruitment of endothelial cells to vessel maturation. This review summarizes tumor angiogenesis and describes the key signaling pathways governing blood vessel development. The role of angiogenesis in various tumor types is discussed, but the focus is on invasive breast cancer, a disease that will affect 182,000 women in the USA in 2008. Research efforts over the past decade have identified numerous potential, as well as proven therapies with activity in breast cancer. These include chemotherapeutics as well as therapies that inhibit specific angiogenic pathways known as targeted agents. Some of the data from single- and multitargeted antiangiogenic agents are described in this review. "Published 2008 Wiley-Liss, Inc. This article is a US Government work, and, as such, is in the public domain in the United States of America."
引用
收藏
页码:1777 / 1787
页数:11
相关论文
共 62 条
[21]  
Foekens JA, 2001, CANCER RES, V61, P5407
[22]  
FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
[23]  
GIANNI L, 2007, BR CANC RES TREAT S1, V106, pS6079
[24]   Genetically tagging endothelial cells in vivo:: bone marrow-derived cells do not contribute to tumor endothelium [J].
Göthert, JR ;
Gustin, SE ;
van Eekelen, JAM ;
Schmidt, U ;
Hall, MA ;
Jane, SM ;
Green, AR ;
Göttgens, B ;
Izon, DJ ;
Begley, CG .
BLOOD, 2004, 104 (06) :1769-1777
[25]   New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF [J].
Holash, J ;
Wiegand, SJ ;
Yancopoulos, GD .
ONCOGENE, 1999, 18 (38) :5356-5362
[26]   Tumor regression by targeted gene delivery to the neovasculature [J].
Hood, JD ;
Bednarski, M ;
Frausto, R ;
Guccione, S ;
Reisfeld, RA ;
Xiang, R ;
Cheresh, DA .
SCIENCE, 2002, 296 (5577) :2404-2407
[27]   Tumor biology - Herceptin acts as an anti-angiogenic cocktail [J].
Izumi, Y ;
Xu, L ;
di Tomaso, E ;
Fukumura, D ;
Jain, RK .
NATURE, 2002, 416 (6878) :279-280
[28]   Management of hypertension in angiogenesis inhibitor-treated patients [J].
Izzedine, H. ;
Ederhy, S. ;
Goldwasser, F. ;
Soria, J. C. ;
Milano, G. ;
Cohen, A. ;
Khayat, D. ;
Spano, J. P. .
ANNALS OF ONCOLOGY, 2009, 20 (05) :807-815
[29]   Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy [J].
Jain, RK .
SCIENCE, 2005, 307 (5706) :58-62
[30]   Mechanisms of adverse effects of anti-VEGF therapy for cancer [J].
Kamba, T. ;
McDonald, D. M. .
BRITISH JOURNAL OF CANCER, 2007, 96 (12) :1788-1795